Speech Date

2026/04/09

Theme

Announcement of the Company's repurchase of treasury shares up to a certain standard.

Fact Date

2026-04-09

Describe

1.Date the cumulative no.of shares currently repurchased
accounted for 2 percent or more of the shares issued
by the company, or amounted to NT$300 million or more:2026/04/09
2.No.of shares currently repurchased (shares):1,605,000
3.Type of shares currently repurchased:Common shares
4.Total monetary amount of shares currently repurchased (NTD):31,189,650
5.Current average repurchase price per share (NTD):19.43
6.Cumulative no.of the company’s own shares held during
the repurchase period (shares):1,605,000
7.Cumulative no.of the company’s own shares held during
the repurchase period as a percentage of the total no.of
the company’s issued shares:2.07%
8.Any other matters that need to be specified:None

Speech Date

2026/03/31

Theme

The Board of Directors has resolved the second buyback of treasury shares

Fact Date

2026-03-30

Describe

1.Date of the board of directors resolution:2026/03/30
2.Purpose of the share repurchase:
To maintain the Company’s credit and shareholders' equity.
3.Type of shares to be repurchased:Common shares
4.Ceiling on total monetary amount of share repurchase (NTD):756,468,000
5.Scheduled period for the repurchase:2026/03/30~2026/05/29
6.No.of shares to be repurchased (shares):3,872,000
7.Repurchase price range (NTD):
14.00~30.00, The Company will continue the buyback as the share price
is below the lower limit of the designated price range.
8.Method for the repurchase:
From the centralized securities exchange market
9.Shares to be repurchased as a percentage of total
issued shares of the company (%): 5%
10.Cumulative no.of the company’s own shares held
at the time of reporting (shares): 0
11.Status of repurchases within three years prior to
the time of reporting: None.
12.Status of repurchases that have been reported but
not yet completed: None.
13.Minutes of the board of directors meeting that resolved
for the share repurchase:
Minutes of the Board Meeting for Share Repurchase
The 23rd Special Meeting of the 8th Board on March 30, 2026:
Proposal: Conduct the 2nd share buyback for cancellation.
Description:
1.Pursuant to Art. 28-2 of the Securities and Exchange Act and
relevant regulations, the details are as follows:
(A) Purpose: To maintain Company’s credit and shareholders’ equity.
(B) Type: Common shares.
(C) Ceiling: Statutory limit NT$756,468K; this buyback NT$116,160K.
(D) Period & Quantity: Mar 30–May 29, 2026; 3,872K shares.
(E) Price: NT$14–30. May continue if price is below lower limit.
(F) Method: Buyback from the OTC market.
(G) Ratio: ~5.00% (Based on 77,449,547 issued shares as of Mar 30).
(H) Current Holdings: 0 shares.
(I) Buybacks in prior 5 years: None.
(J) Unfinished prior buybacks: None.
(K) Board Declaration: Financial condition considered; see Att. 1.
2.Per Para. 1, Art. 28-2 of the Act, the buyback was approved
by a majority of the 2/3 directors present.
3.Chairman is authorized to handle the buyback. Execution status
will be reported at the next Shareholders' Meeting.
4.Per Para. 6, Art. 28-2 of the Act, shares held by affiliates,
directors, supervisors, managers, and their relatives shall not
be sold during the buyback period.
5.Approved by Audit Committee and submitted to the Board.
Resolution: Passed unanimously as originally proposed.
14.The Rules for Transfer of Shares set forth in Article
10 of the Regulations Governing Share Repurchase by
TWSE-listed and TPEx-Listed Companies: NA
15.The Rules for Conversion of Shares or the Rules for
Subscription of Shares set forth in Article 11 of the
Regulations Governing Share Repurchase by TWSE-listed
and TPEx-Listed Companies: NA
16.Declaration that the financial status of the company
has been considered by the board of directors, and that
its capital maintenance will not be affected:
1. The 23rd Special Meeting of the 8th Board on March 30, 2026,
attended by over 2/3 of directors and approved by a majority of
present directors, resolved to buy back 3,872,000 common shares
from the OTC market within 2 months from the reporting date.
2. The total shares to be repurchased account for only 5% of the
issued shares. The maximum amount of NT$116,160K represents only
2.11% of the Company's current assets (NT$5,513,051K) based on
the audited consolidated financial statements as of Dec 31, 2025.
The Board declares that the financial condition has been
considered and the buyback will not affect the maintenance of
the Company's capital.
3. This declaration was approved at the same Board meeting with
the consent of all 8 directors present.
Cowealth Medical Holding Co., Ltd.
Chairman: Wang Chiung Chih
17.Appraisal or opinion by a CPA or securities underwriter
about the reasonableness of the share repurchase price:
According to the opinion of Grand Fortune Securities Co., Ltd.,
the price range for this share buyback is reasonable and
complies with relevant regulations.
Based on the evaluation, the impact on the Company’s financial
structure, net value per share, earnings per share (EPS),
return on equity (ROE), current ratio, quick ratio, and cash
flow is not significant to the Company’s overall financial
condition or shareholders' equity.
18.Any other matters stipulated by the SFB:None.

Speech Date

2026/03/31

Theme

Board of Directors resolved to supplement the notice for the 2026 Annual General Shareholders’ Meeting (Additions to the meeting agenda)

Fact Date

2026-03-30

Describe

1.Date of the board of directors' resolution：2026/03/30
2.Shareholders meeting date：2026/05/20
3.Shareholders meeting location：Cowealth Center of 23F, No. 76,Sec. 2, Dunhua S. Rd., Da’an Dist.,
Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders' meeting will be held by means of (physical shareholders' meeting/ hybrid shareholders' meeting / virtual-only shareholders' meeting)：physical shareholders' meeting
5.Cause for convening the meeting (1)：Report item(s)
(1)：2025annual business report
(2)：Audit Committee's review of the 2025 annual final accounting books
and statements
(3)：Report on 2025 employees' and directors' remuneration
(4)：Report on 2025 director compensation
(5)：Report on communications between the Audit Committee and the Head of
Internal Audit for 2025
(6)：Report on the 2026 concrete implementation plan for sustainable
development
(7)：Report on the 2026 share buyback progress
6.Cause for convening the meeting (2)：Ratification Item(s)
(1)：2025 annual financial statements and business report
(2)：2025 earnings distribution
7.Cause for convening the meeting (3)：Discussion Item(s)
(1)：Amendments to the "Articles of Association"
(2)：Amendments to the "Procedures for Acquisition or Disposal of Assets
Management"
8.Cause for convening the meeting (4)：Election Item
(1)：Proposal for Full Re-election of the Board of Directors
9.Cause for convening the meeting (5)：Other Proposal(s)
(1)：Removal of Non-Compete Restrictions for the 9th Board Directors of the Company
10.Extemporary Motions：
11.Book closure starting date：2026/03/22
12.Book closure ending date：2026/05/20
13.Any other matters that need to be specified：In accordance with the laws of the Republic of China, the
following matters related to the acceptance of shareholder
proposals in writing are established:
(1)Acceptance period: From March 6, 2026, to March 16, 2026.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(3) Acceptance Location: Taiwan Branch of Cowealth Holing Company
(4) Proposal Eligibility: Shareholders who hold more than 1% of
the total issued shares (whether individually or collectively).
(5) Proposal Method:
Shareholders intending to submit a proposal must do so in
writing by 5:00 PM on March 16, 2026, and each shareholder may
submit only one proposal. Proposals exceeding one item will not
be included in the agenda. Each proposal shall be limited to 300
Chinese characters; proposals exceeding this limit will not be
included in the agenda.
(6) Other Matters Related to Shareholder Proposals: Any matters
not covered regarding shareholder proposals will be handled
according to relevant laws and regulations. Whether or not a
proposal will be excluded from the agenda according to the
company's articles of association will be reviewed by the board
of directors after the proposal acceptance period has ended.
The detailed content of the accepted proposals will be based on
the company's public announcements on the Market Observation
Post System.
For this shareholder meeting, shareholders will exercise
their voting rights electronically. Relevant details are as
follows:
(1) Voting Period: Extended from March 6, 2026, to March 26, 2026.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(Taiwan Branch of Cowealth Holing Company)
(3) Proposal Eligibility: Shareholders who hold more than 1% of
the total issued shares (whether individually or collectively).
(4) Nomination Method:
There are four director positions and four independent director
positions to be elected. Shareholders intending to nominate
candidates for directors (including independent directors) must
submit a written nomination by 5:00 PM on March 26, 2026,
including the nominator's information and the nominee's name,
educational and professional background, and supporting
documents demonstrating compliance with the qualifications for
independent directors. Nominations exceeding the number of
positions to be elected, or nominees not meeting statutory
qualifications, will not be included in the candidate list.

Electronic Voting for the Shareholders' Meeting
(1) Voting Period: From April 20, 2026, to May 17, 2026.
(2) Electronic Voting Platform: Taiwan Depository & Clearing
Corporation, website: https://www.stockvote.com.tw

Speech Date

2026/03/31

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for February 2026

Fact Date

2026-03-31

Describe

1.Date of occurrence of the event:2026/03/31
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of February, the Company's accounts receivable balance
is NT$3,719,979 thousand (including overdue accounts receivable
of NT$1,973,713 thousand and non-overdue accounts receivable
of NT$1,746,266 thousand), accounting for 53.50% of total assets
and 480.31% of Common Stock. The amount recieved in February
was NT$212,314 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
Since 2026, the Company has strengthened its accounts receivable
collection mechanism. For overdue accounts and customers with
potential bad debt risks, the Chairman & CEO, CFO, and Financial
Analysis Manager are now responsible for tracking and supervision
based on the transaction amounts and risk levels.
The collection amount in February significantly increased by 56%
compared to the previous month. Moving forward, the Company will
continue to implement collection measures and enhance accounts
receivable management to mitigate overall credit risk and improve the
efficiency of capital recovery.

Speech Date

2026/03/13

Theme

Board of Directors resolved to supplement notice for 2026 Annual General Shareholders' Meeting (Regarding Nominations for Directors and Independent Directors)

Fact Date

2026-03-13

Describe

1.Date of the board of directors' resolution：2026/03/13
2.Shareholders meeting date：2026/05/20
3.Shareholders meeting location：Cowealth Center of 23F, No. 76,Sec. 2, Dunhua S. Rd., Da’an Dist.,
Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders' meeting will be held by means of (physical shareholders' meeting/ hybrid shareholders' meeting / virtual-only shareholders' meeting)：physical shareholders' meeting
5.Cause for convening the meeting (1)：Report item(s)
(1)：2025annual business report
(2)：Audit Committee's review of the 2025 annual final accounting
books and statements
(3)：Report on 2025 employees' and directors' remuneration
(4)：Report on 2025 director compensation
6.Cause for convening the meeting (2)：Ratification Item(s)
(1)：2025 annual financial statements and business report
(2)：2025 earnings distribution
7.Cause for convening the meeting (3)：Discussion Item(s)
(1)：Amendments to the "Articles of Association"
(2)：Amendments to the "Procedures for Acquisition or Disposal of
Assets Management"
(3)：Amendments to the "The Rules of Procedure for Shareholders Meetings"
8.Cause for convening the meeting (4)：Election Item
(1)：Proposal for Full Re-election of the Board of Directors
9.Cause for convening the meeting (5)：Other Proposal(s)
(1)：Removal of Non-Compete Restrictions for the 9th Board Directors
of the Company
10.Extemporary Motions：
11.Book closure starting date：2026/03/22
12.Book closure ending date：2026/05/20
13.Any other matters that need to be specified：In accordance with the laws of the Republic of China, the following
matters related to the acceptance of shareholder proposals in writing
are established:
(1) Acceptance period: From March 6, 2026, to March 16, 2026.
(2) Acceptance location: 23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(3) Acceptance Location: Taiwan Branch of Cowealth Holing Company
(4) Proposal Eligibility: Shareholders who hold more than 1% of the
total issued shares (whether individually or collectively).
(5) Proposal Method:
Shareholders intending to submit a proposal must do so in writing
by 5:00 PM on March 16, 2026, and each shareholder may submit only
one proposal. Proposals exceeding one item will not be included in
the agenda. Each proposal shall be limited to 300 Chinese
characters; proposals exceeding this limit will not be included in
the agenda.
(6) Other Matters Related to Shareholder Proposals: Any matters not
covered regarding shareholder proposals will be handled according
to relevant laws and regulations. Whether or not a proposal will
be excluded from the agenda according to the company's articles of
association will be reviewed by the board of directors after the
proposal acceptance period has ended. The detailed content of the
accepted proposals will be based on the company's public
announcements on the Market Observation Post System.

For this shareholder meeting, shareholders will exercise their voting
rights electronically. Relevant details are as follows:
(1) Voting Period: Extended from March 6, 2026, to March 26, 2026.
(2) Acceptance location: 23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(Taiwan Branch of Cowealth Holing Company)
(3) Proposal Eligibility: Shareholders who hold more than 1% of the
total issued shares (whether individually or collectively).
(4) Nomination Method:
There are four director positions and four independent director
positions to be elected. Shareholders intending to nominate
candidates for directors (including independent directors) must
submit a written nomination by 5:00 PM on March 26, 2026, including
the nominator's information and the nominee's name, educational and
professional background, and supporting documents demonstrating
compliance with the qualifications for independent directors.
Nominations exceeding the number of positions to be elected, or
nominees not meeting statutory qualifications, will not be included
in the candidate list.

Electronic Voting for the Shareholders' Meeting
(1) Voting Period: From April 20, 2026, to May 17, 2026.
(2) Electronic Voting Platform: Taiwan Depository & Clearing
Corporation, website: https://www.stockvote.com.tw

Speech Date

2026/03/13

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the year of 2025

Fact Date

2026-03-13

Describe

1.Date of the board of directors submitted or approved:2026/03/13
2.Date of the audit committee approved:2026/03/13
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2025/01/01~2025/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):2,956,257
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):392,176
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(275,424)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(285,297)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(331,106)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(246,557)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(3.18)
11.Total assets end of the period (thousand NTD):7,042,105
12.Total liabilities end of the period
(thousand NTD):1,985,415
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,870,165
14.Any other matters that need to be specified:None

Speech Date

2026/03/13

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2026-03-13

Describe

1.Date of occurrence of the event:2026/03/13
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 54.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the 2025 Annual Report and its Summary
of the Company
2、Resolutions Regarding the 2025 Board of Directors' Work Report
of the Company
3、Resolutions Regarding the 2025 Independent Directors' Performance Report
of the Company
4、Resolutions Regarding the Self-assessment of Independence of
Independent Directors
5、Resolutions Regarding the 2025 General Manager's Work Report
of the Company
6、Resolutions Regarding the 2025 Audit Committee's Performance Report
of the Company
7、Resolutions Regarding the Performance Evaluation Report of the
Accounting Firm for the Year 2025 and the Report on the Supervisory
Duties Performed by the Audit Committee
8、Resolutions Regarding the 2025 Financial Statements Report of the Company
9、Resolutions Regarding the 2025 Internal Control Evaluation Report of the
Company
10、Resolutions Regarding the Special Report on the Utilization of Raised
Funds and its Actual Usage in 2025
11、Resolutions Regarding the 2026 Audit Plan of the Company
12、Resolutions Regarding Amend the Director Compensation Management
Policy
13、Resolutions Regarding the 2026 Remuneration Plan for the company's
directors of the Company
14、Resolutions Regarding the 2026 Compensation Plan for Senior Management
Personnel of the Company
15、Resolutions Regarding the Proposed Profit Distribution Plan for the
Year 2025
16、Resolutions Regarding the Plan for the Guarantee Quota for the Year 2026
of the Company
17、Resolutions Regarding the company's application for credit facilities
from banks and other financial institutions.
18、Resolutions Regarding the company's use of temporarily idle self-owned
funds for entrusted wealth management.
19、Resolutions Regarding the Proposal to Convene the 2025 Annual General
Meeting of Shareholders
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2026/03/13

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolution by the Board of Directors not to Distribute Dividends

Fact Date

2026-03-13

Describe

1.Date of the board of directors resolution:2026/03/13
2.Type and monetary amount of dividend distribution:
Not to Distribute Dividends
3.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2026/03/13

Theme

Announcement of Board of Directors' Resolution Not to Distribute Dividends

Fact Date

2026-03-13

Describe

1.Date of the board of directors resolution:2026/03/13
2.Year or quarter which dividends belong to :2025
3.Period which dividends belong to:2025/01/01~2025/12/31
4.Appropriations of earnings in cash dividends to shareholders (NT$
per share):0
5.Cash dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
6.Total amount of cash dividends to shareholders (NT$):0
7.Appropriations of earnings in stock dividends to shareholders (NT$
per share):0
8.Stock dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
9.Total amount of stock dividends to shareholders (shares):0
10.Any other matters that need to be specified:None
11.Per value of common stock:NT$10

Speech Date

2026/03/05

Theme

Announcement of the Board of Directors meeting date for the Consolidated Financial Report for the year of 2025

Fact Date

2026-03-05

Describe

1.Date of a notice of the board of directors meeting is issued:2026/03/05
2.Expected date of the board of directors meeting is convened:2026/03/13
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:The Consolidated Financial Report for the year of 2025
4.Any other matters that need to be specified:None

Speech Date

2026/03/02

Theme

Board of Directors resolved to convene the 2026 Annual General Shareholders’ Meeting

Fact Date

2026-03-02

Describe

1.Date of the board of directors' resolution：2026/03/02
2.Shareholders meeting date：2026/05/20
3.Shareholders meeting location：Cowealth Center of 23F, No. 76,Sec. 2, Dunhua S. Rd.,
Da’an Dist., Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders' meeting will be held by means of (physical shareholders' meeting/ hybrid shareholders' meeting / virtual-only shareholders' meeting)：physical shareholders' meeting
5.Cause for convening the meeting (1)：Report item(s)
(1)：2025 annual business report
(2)：Audit Committee's review of the 2025 annual final accounting books
and statements
(3)：Report on 2025 employees' and directors' remuneration
(4)：Report on 2025 director compensation
6.Cause for convening the meeting (2)：Ratification Item(s)
(1)：2025 annual financial statements and business report
(2)：2025 earnings distribution
7.Cause for convening the meeting (3)：Discussion Item(s)
(1)：Amendments to the "Articles of Association"
(2)：Amendments to the "Procedures for Acquisition or Disposal of
Assets Management"
(3)：Amendments to the "The Rules of Procedure for Shareholders Meetings"
8.Cause for convening the meeting (4)：Election Item
(1)：Proposal for Full Re-election of the Board of Directors
9.Extemporary Motions：
10.Book closure starting date：2026/03/22
11.Book closure ending date：2026/05/20
12.Any other matters that need to be specified：In accordance with the laws of the Republic of China,
the following matters related to the acceptance of shareholder
proposals in writing are established:

(1)Acceptance period: from March 7, 2025 to March 17, 2025.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da’an Dist., Taipei City 106485, Taiwan (R.O.C.)
(3) Acceptance Location: Taiwan Branch of Allied Healthcare
Medical Equipment Co., Ltd., a company incorporated in the
Cayman Islands.
(4) Proposal Eligibility: Shareholders who hold more than 1% of
the total issued shares (whether individually or collectively).
(5) Proposal Method:

• Any proposal submitted by a shareholder must be made in writing
and submitted no later than 17:00 on March 16, 2026, and shall be
limited to one proposal only. If more than one proposal is
submitted, none will be included in the meeting agenda.
Proposals shall be limited to 300 words; proposals exceeding
300 words will not be included in the agenda.

• Shareholders intending to nominate candidates for director
(including independent director) positions shall submit their
nominations in writing by 17:00 on March 16, 2026, together with
documentation specifying the nominator’s information and the
nominee’s name,education and work experience, and evidence
demonstrating qualifications for independent director
eligibility. If the number of nominees exceeds the number of
available seats or the nominees do not meet statutory
qualification requirements, they will not be included in the
candidate list

(6) Other Matters Related to Shareholder Proposals: Any matters
not covered regarding shareholder proposals will be handled
according to relevant laws and regulations. Whether or not a
proposal will be excluded from the agenda according to the
company’s articles of association will be reviewed by the
board of directors after the proposal acceptance period has
ended. The detailed content of the accepted proposals will
be based on the company’s public announcements on the Market
Observation Post System.

For this shareholder meeting, shareholders will exercise their
voting rights electronically. Relevant details are as follows:
(1) Voting Period: From April 20, 2026, to May 17, 2026.
(2) Electronic Voting Platform: Taiwan Depository & Clearing
Corporation, website: https://www.stockvote.com.tw

Speech Date

2026/03/02

Theme

Announcement of the Board of Directors’ Appointment of the Corporate Governance Officer

Fact Date

2026-03-02

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Corporate Governance Officer
2.Date of occurrence of the change:2026/03/02
3.Name, title, and resume of the previous position holder:N/A
4.Name, title, and resume of the new position holder:
Cathy, Juan / Accounting Officer
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):new replacement
6.Reason for the change:new replacement
7.Effective date:2026/03/02
8.Any other matters that need to be specified:N/A

Speech Date

2026/03/02

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the Regarding Civil Litigation Matters

Fact Date

2026-03-02

Describe

1.Parties to the legal matter:
Plaintiff/ Defendant: Guangdong Second Provincial General Hospital
Plaintiff/ Defendant: Cowealth Medical China Co., Ltd.
2.Name of the court or punishing agency of the legal matter:
Haizhu District People’s Court of Guangzhou
3.Reference/Case number of relevant documents of the legal matter:
Case No. (2025) Yue 0105 Min Chu No. 42651
4.Date of occurrence of the event:2026/03/02
5.Details of occurrence (including the matter under dispute):
The Company’s subsidiary, Cowealth Medical China Co., Ltd., (hereinafter
referred to as “The Company”) and Guangdong Second People’s Hospital
(hereinafter referred to as the “Hospital”) established a five-year reagent
supply chain integration cooperation in June 2020. Due to the Hospital’s
breach of contract and the failure of negotiations, The Company filed a
lawsuit with the Haizhu District People’s Court of Guangzhou Municipality
regarding a dispute over the reagent sales contract, with an amount in
dispute of RMB 48,878,323.02. The Haizhu District People’s Court of
Guangzhou Municipality accepted the case on April 28, 2025. On
September 10, 2025, the Hospital filed a counterclaim in relation to the
same reagent sales contract dispute, with a counterclaim amount of RMB
5,836,146.
In 2018, The Company and the Hospital commenced cooperation on the
clinical trial of radiotherapy equipment and subsequently reached an
intention for procurement and retention of the equipment. As the Hospital
ultimately failed to perform its obligation to procure the radiotherapy
equipment, resulting in losses to the Company, and negotiations between
the parties failed, The Company separately filed a lawsuit in April 2025 with
the Pudong New Area People’s Court of Shanghai Municipality regarding a
dispute over the radiotherapy equipment sales contract, with an amount in
dispute of RMB 50,877,893.90. The Pudong New Area People’s Court of
Shanghai Municipality accepted the case on August 20, 2025.
In respect of the same radiotherapy equipment sales contract dispute, the
Hospital also filed a lawsuit with the Haizhu District People’s Court of
Guangzhou Municipality, alleging that The Company’s delay in delivering
the equipment caused losses to the Hospital, with an amount in dispute of
RMB 30,362,772.84. On February 27, 2026, The Company a received a
Summons (Case No. (2025) Yue 0105 Min Chu No. 42651) and other
litigation materials issued by the Haizhu District People’s Court of
Guangzhou Municipality.
6.Handling procedure:
The Company has engaged legal counsel to handle the subsequent
proceedings in order to fully safeguard the legitimate rights and interests
of the Company and all its shareholders.
7.Impact on the Company’s finance and business and projected amount:
The case has not yet been heard in court, and the final judgment remains
uncertain. The impact on the Company’s current or subsequent profits
cannot be accurately estimated at this stage. The Company will carry out
the relevant accounting treatment in accordance with the actual progress of
the case and the requirements of accounting standards. The Company will
duly fulfill its information disclosure obligations regarding subsequent
developments of this litigation matter.
8.Countermeasures and improvement status:
The Company has appointed legal counsel to take the necessary measures
in accordance with the relevant litigation procedures and regulations.
9.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 2
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
For details of the above announcement, please refer to the disclosure
website of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2026/02/25

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for January 2026

Fact Date

2026-02-25

Describe

1.Date of occurrence of the event:2026/02/25
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of January, the Company's accounts receivable balance
is NT$3,643,529 thousand (including overdue accounts receivable
of NT$1,697,248 thousand and non-overdue accounts receivable
of NT$1,946,281 thousand), accounting for 52.40% of total assets
and 470.44% of Common Stock. The amount recieved in January
was NT$136,078 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
Since 2026, the Company has strengthened its accounts receivable
collection mechanism. For overdue accounts and customers with
potential bad debt risks, the Chairman & CEO, CFO, and Financial
Analysis Manager are now responsible for tracking and supervision
based on the transaction amounts and risk levels.
Currently, some hospitals have proposed concrete repayment plans in
accordance with the Company’s collection mechanism. Moving forward,
the Company will continue to implement collection measures and
enhance accounts receivable management to mitigate overall credit risk
and improve the efficiency of capital recovery.

Speech Date

2026/01/30

Theme

(Correction to Jan 29 Announcement) Announcement of the Change of Corporate Governance Officer

Fact Date

2026-01-29

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Corporate Governance Officer
2.Date of occurrence of the change:2026/01/29
3.Name, title, and resume of the previous position holder:
Qiao, Jessica/ Corporate Governance Officer
4.Name, title, and resume of the new position holder:
To be appointed by the Board
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):Resignation
6.Reason for the change:Resignation
7.Effective date:2026/01/29
8.Any other matters that need to be specified:
The official appointees will be announced after the
formal appointment by the Board of Directors.

Speech Date

2026/01/29

Theme

Announcement of the change of Corporate Governance Officer

Fact Date

2026-01-29

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Corporate Governance Officer
2.Date of occurrence of the change:2026/01/29
3.Name, title, and resume of the previous position holder:
Qiao, Jessica/ Corporate Governance Officer
4.Name, title, and resume of the new position holder:
To be appointed by the Board
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):Resignation
6.Reason for the change:Resignation
7.Effective date:2026/01/29
8.Any other matters that need to be specified:
The official appointees will be announced after the
formal appointment by the Board of Directors.

Speech Date

2026/01/22

Theme

Correction to the Company's reported information on Endorsements and Guarantees for December 2025

Fact Date

2026-01-22

Describe

1.Date of occurrence of the event:2026/01/22
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head
office” or ”subsidiaries”):
head office and its subsidiaries(”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
Correction to the Company's reported information on Endorsements and
Guarantees for December 2025
6.Information items/ statements to be corrected:
The Company's reported information on Endorsements and Guarantees
for December 2025
7.Amounts/ contents/ number of page to be corrected:
Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Colab Reserch & Development Inc.
Amount of increase (decrease) for the individual subsidiary this month:
129,645 thousand

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Coaim Information Technology Co.,Ltd.
Amount of increase (decrease) for the individual subsidiary this month:
129,645 thousand

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: CHM Consulting Co., Ltd.
Amount of increase (decrease) for the individual subsidiary this month:
43,215 thousand

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Royal Seal Holding Co., Limited
Amount of increase (decrease) for the individual subsidiary this month:
864,300 thousand

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Cowealth Medical Shanghai Co., Ltd.
Amount of increase (decrease) for the individual subsidiary this month:
129,645 thousand
8.Amounts/ contents/ number of page after correction:
Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Colab Reserch & Development Inc.
Amount of increase (decrease) for the individual subsidiary this month:0

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Coaim Information Technology Co.,Ltd.
Amount of increase (decrease) for the individual subsidiary this month:0

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: CHM Consulting Co., Ltd.
Amount of increase (decrease) for the individual subsidiary this month:0

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Royal Seal Holding Co., Limited
Amount of increase (decrease) for the individual subsidiary this month:0

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Cowealth Medical Shanghai Co., Ltd.
Amount of increase (decrease) for the individual subsidiary this month:0
9.Countermeasures:
To proceed in accordance with the regulations specified in the letter.
10.Any other matters that need to be specified:None

Speech Date

2026/01/16

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for December 2025

Fact Date

2026-01-16

Describe

1.Date of occurrence of the event:2026/01/16
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of November, the Company's accounts receivable balance
is NT$3,456,606 thousand (including overdue accounts receivable
of NT$1,536,638 thousand and non-overdue accounts receivable
of NT$1,919,968 thousand), accounting for 49.94% of total assets
and 446.30% of Common Stock. The amount recieved in December
was NT$411,295 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
The Company has actively promoted the collection of accounts
receivable, resulting in a decrease of 93,855 thousand in the balance for
the current quarter compared to the previous quarter. Additionally, the
actions and strengthen its accounts receivable management mechanism
to reduce credit risk.

Speech Date

2026/01/01

Theme

Subsidiary Cowealth (HK) proposes to dispose of equity in material subsidiary Cowealth (China).

Fact Date

2025-12-31

Describe

1.Name of the securities:
Equity of Cowealth (China) Medical Technology Co., Ltd.
2.Trading date:2025/12/24~2025/12/31
3.Amount, unit price, and total monetary amount of the
transaction:
(1).Transaction volume: 3,980,000 shares
(2).Unit price: Average price of RMB 24.923 per unit
(3).Total transaction amount: RMB 99,193,707
(approximately NTD 438,713,927)
4.Gain (or loss) through disposal (not applicable in
case of acquisition of securities):
Pursuant to IFRS, the Company retains control over the
subsidiary after the disposal; thus, no gain or loss is
recognized.
5.Relationship with the underlying company of the trade:
Material subsidiary of the Company
6.Current cumulative amount held, monetary value, and
shareholding percentage of cumulative holdings of the
securities being traded (including the current trade),
and status of any restriction of rights (e.g., pledges):
Cumulative amount held:
(1).Cumulative amount held: 218,937,885 shares
(2).Monetary value: Based on Cowealth (China)'s closing
price on Dec 31, the cumulative total amount is
NTD 23,197,463.90
(3).Shareholding percentage: 54%
(4).Status of any restriction of rights: None
7.Current ratio of securities investment (including the
current trade) to the total assets and equity attributable
to owners of parent as shown in the most recent financial
statement and working capital as shown in the most recent
financial statement as of the present, as listed in the
Regulations Governing the Acquisition and Disposal of
Assets by Public Companies: Ratio to total assets:6.60%
Ratio to equity attributable to owners of parent:17.06%
Working capital:NTD 3,606,029 thousand
8.Concrete purpose of the acquisition or disposal:
To respond to the current competitive market environment
and business development needs, and to enhance the Group's
overall operational efficiency and shareholder returns by
adjusting the shareholding structure.
9.Whether the directors expressed any objection to
the current transaction:None
10.Whether the counterparty of the current transaction
is a related party:Yes
11.Trading counterparty and its relationship to the
Company:Material subsidiary of the Company
12.Date of the board of directors’ resolution:2025/11/21
13.Date of ratification by supervisors or approval by
the audit committee:2025/11/21
14.Any other matters that need to be specified:
(1).On October 17, 2025, the Company received an approval
letter from the Taipei Exchange (TPEx) regarding the
adjustment to include ”the disposal of existing shareholdings
in Cowealth (China)” to reduce the ownership in Cowealth
(China) to above 51%.
(2).The Company's subsidiary, Cowealth (Hong Kong) Holding
Co., Ltd., currently holds 55% equity in Cowealth (China).
It proposes to dispose of equity not exceeding 4%, and the
Chairman is authorized with full authority to handle all
related matters.